Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, talks on the use of multi-omic methods to characterize response to CAR-T therapy in multiple myeloma. Dr Lin explains that emerging data is showing that bone marrow MRD status could predict the durability of response and identify patients at risk of relapse. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.